-
(S)-(+)-Dimethindene maleate: Lab Guide
2026-09-15
This guide explains how to use (S)-(+)-Dimethindene maleate, SKU B6734, when an experiment requires pharmacological perturbation of M2 muscarinic and H1 histamine receptors. It focuses on assay setup, solution handling, controls, and interpretation boundaries rather than therapeutic or diagnostic use.
-
hCG, H3K27 Methylation, and CXCL10 in Decidua
2026-09-15
Silasi and colleagues showed that human chorionic gonadotropin suppresses decidual CXCL10 by promoting EZH2-dependent H3K27me3 deposition at the CXCL10 promoter. This mechanism links placental endocrine signaling with local control of CD8-cell recruitment and provides a useful framework for studying epigenetic regulation at the maternal–fetal interface.
-
Linezolid vs MmpL3: A Smarter Assay Strategy
2026-09-14
Linezolid provides a mechanistically defined benchmark for inhibition of bacterial protein synthesis, while spirocyclic POM compound 5c illustrates target-led tuberculosis discovery. This article shows how to compare these systems without confusing assay potency, species biology, or translational maturity.
-
Methylprednisolone: Reliable Assay Workflows
2026-09-14
This scenario-based guide shows how Methylprednisolone SKU A4233 can support reproducible inflammatory, viability, proliferation, and glucocorticoid-injury workflows. It combines practical formulation guidance with evidence from macrophage, immune-cell, and methylprednisolone-induced osteonecrosis research.
-
LGK-974: Translating PORCN Inhibition into Wnt Strategy
2026-09-13
A translational framework for using LGK-974 as a PORCN inhibitor to interrogate Wnt dependency, pancreatic cancer RNF43 mutation biology, pathway biomarkers, and combination strategies in Wnt-driven cancer research.
-
Vidarabine monohydrate: Assay Design
2026-09-12
Vidarabine monohydrate is more than a conventional antiviral reference compound. This guide presents a mechanism-to-measurement framework for controlling solubility, separating antiviral activity from cytotoxicity, and using orthogonal assays to interpret viral DNA synthesis results.
-
DiscoveryProbe™ Metabolism-related Compound Library
2026-09-12
The DiscoveryProbe™ Metabolism-related Compound Library provides a standardized set of 493 metabolism-focused small molecules for enzyme, pathway, cell-based, and ex vivo screening. It is intended for research use only; compound-specific activity, selectivity, toxicity, and clinical relevance must be established experimentally rather than inferred from the library description.
-
Deferasirox in Ferroptosis Research
2026-09-11
Deferasirox is an oral iron chelator that helps researchers manipulate labile iron, ferroptosis resistance, and tumor-cell stress in controlled models. This guide translates the METTL16-SENP3-LTF findings in hepatocellular carcinoma into practical dosing, assay, workflow, and troubleshooting decisions.
-
TH287 MTH1 Inhibitor: Mechanism and Radiosensitization
2026-09-11
TH287 is a potent MTH1 inhibitor that exposes cancer cells to oxidized-nucleotide stress and DNA damage. Evidence in castration-resistant prostate cancer models indicates that treatment timing can influence TH287-associated radiosensitization.
-
SB203580: Rethinking p38 Inhibition
2026-09-10
SB203580 is more than a conventional p38 MAP kinase inhibitor. This thought-leadership article connects its ATP-competitive pharmacology with emerging evidence that kinase inhibitors can reshape activation-loop accessibility and phosphatase-driven signal termination, providing a practical framework for translational research in inflammation, neuroprotection, and adaptive resistance.
-
ONX-0914 (PR-957) Experimental Workflows
2026-09-10
ONX-0914 (PR-957) provides selective LMP7 inhibition for separating immunoproteasome biology from constitutive proteasome effects. This practical guide connects cytokine assays, autoimmune disease models, and a reference-informed hippocampal workflow with formulation, dosing, and troubleshooting strategies.
-
SU5416 (Semaxanib) for Vascular Remodeling Studies
2026-09-09
SU5416 (Semaxanib) enables controlled VEGFR2 blockade across endothelial, tumor, and vascular-remodeling models. This guide connects practical angiogenesis workflows with subject-specific pulmonary hemodynamics, while addressing dosing, solvent handling, assay selection, and interpretation limits.
-
Wnt agonist 1: Applied Research Workflows
2026-09-09
Wnt agonist 1 (BML-284) provides a controllable small-molecule approach for canonical Wnt signaling pathway activation, from differentiation assays to developmental models. This guide translates the Wnt/NR2F2/GPX4 chemoresistance findings into practical experimental designs while separating validated evidence from testable extensions.
-
Z-VAD-FMK Workflows for Apoptosis Research
2026-09-08
Use Z-VAD-FMK to distinguish caspase-dependent apoptosis from persistent cell death, while preserving orthogonal readouts for inflammasome signaling and pyroptotic outcomes. This workflow combines disciplined stock handling, time-resolved caspase activity measurement, and structural insight from full-length ASC research.
-
Luminescent ATP Cell Viability Assay Kit I: Ferroptosis
2026-09-08
Learn how the Luminescent ATP Cell Viability Assay Kit I converts ATP abundance into a rapid, sensitive viability endpoint for ciprofloxacin–RSL3 ferroptosis studies. This guide focuses on experimental interpretation, assay design, and the limits of ATP-based conclusions.